As of November 7, 2026, Contineum Therapeutics, Inc. is a publicly traded company (Nasdaq: CTNM); its largest reported holder is Fidelity (FMR), with 7.9% on Schedule 13G of November 5, 2026, then Janus Henderson (7.9%). The largest insider holding is Daniel S. Lorrain, the chief scientific officer, with 145,312 shares (0.63% of shares outstanding), per Form 4 of July 10, 2026 (Schedule 13G, November 5, 2026).
Is this your company?
About to sign with, pay or invest in Contineum Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Contineum Therapeutics, Inc. a real, registered company?
- Contineum Therapeutics, Inc. files with the SEC under CIK 1855175 (its SEC filings).
- Its shares are listed under the ticker CTNM on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in San Diego, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Contineum Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-07).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Johnson & Johnson Innovation - JJDC, Inc. (filed 2026-11-06).
Who are Contineum Therapeutics, Inc.'s owners and officers?
Contineum Therapeutics, Inc.: incorporated in Delaware; business address in San Diego, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-11-06).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-06 | Johnson & Johnson Innovation - Jjdc, Inc. | 5.6% |
| Schedule 13G, 2026-11-05 | Fmr LLC | 7.9% |
| Schedule 13G/A, 2026-10-28 | Franklin Templeton, Inc. | 5.2% |
| Schedule 13G, 2026-10-28 | Squadron Master Fund LP | 5.1% |
| Schedule 13G, 2026-10-22 | Trails Edge Capital Partners, LP | 5.1% |
| Schedule 13G/A, 2026-08-14 | Balyasny Asset Management L.P. | 7.14% |
| Schedule 13G, 2026-07-27 | Blackrock, Inc. | 6.3% |
| Schedule 13G/A, 2026-07-17 | Millennium Management LLC | 2.8% |
| Schedule 13G, 2026-05-15 | Balyasny Asset Management L.P. | 7.4% |
| Schedule 13G/A, 2026-05-15 | Ra Capital Management, L.P. | 4% |
| Schedule 13G, 2026-04-17 | Millennium Management LLC | 5.1% |
| Schedule 13G, 2026-02-17 | Janus Henderson Group PLC | 7.9% |
Questions about who owns Contineum Therapeutics, Inc.
Who owns Contineum Therapeutics, Inc.?
On this page, 8 holders' latest ownership filings report 5% or more of Contineum Therapeutics, Inc.: Fmr LLC (7.9%, Schedule 13G, filed 2026-11-05), Janus Henderson Group PLC (7.9%, Schedule 13G, filed 2026-02-17), Balyasny Asset Management L.P. (7.14%, Schedule 13G/A, filed 2026-08-14), Blackrock, Inc. (6.3%, Schedule 13G, filed 2026-07-27) and Johnson & Johnson Innovation - Jjdc, Inc. (5.6%, Schedule 13G/A, filed 2026-11-06); 3 more are listed above.
Who are the largest shareholders of Contineum Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Contineum Therapeutics, Inc. on this page are Fmr LLC (7.9%), Janus Henderson Group PLC (7.9%) and Balyasny Asset Management L.P. (7.14%).
When did Fmr LLC buy into Contineum Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G, filed 2026-11-05, reporting 7.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Contineum Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Contineum Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Contineum Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Contineum Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief scientific officer: 145,312 shares (0.63% of shares outstanding), 135,202 held directly and 10,110 indirectly (Form 4, 2026-07-10).
- , the chief executive and president: 17,217 shares (0.07% of shares outstanding) (Form 4, 2026-09-08).
- , the chief marketing officer and head of development: 8,961 shares (0.04% of shares outstanding) (Form 4, 2026-07-01).
Shares outstanding: 23,099,173 as of 2025-10-27, from the company's latest SEC cover page.
How much has Contineum Therapeutics, Inc. raised?
No fundraising or offering filing from Contineum Therapeutics, Inc. is on file with us.
Keep reading
More on Contineum Therapeutics, Inc. and the records around it.
Contineum Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
Companies that share a holder
- Johnson & Johnson Innovation - JJDC, Inc. also filed stake reports on 1 other company: TRex Bio, Inc. (Oct 2026)
- Squadron Master Fund LP also filed stake reports on 14 other companies: TCGX Acquisition Corp. II (Oct 2026), C4 Therapeutics, Inc. (Aug 2026), NextCure, Inc. (Aug 2026)
- Trails Edge Capital Partners, LP also filed stake reports on 16 other companies: Avalo Therapeutics, Inc. (Oct 2026), Sol-Gel Technologies Ltd. (Oct 2026), Faeth Therapeutics, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/contineum-therapeutics